Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Bartelink H, et al. Among authors: van limbergen e. Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Lancet Oncol. 2015. PMID: 25500422 Clinical Trial.
Local control of operable breast cancer after radiotherapy alone.
Van Limbergen E, Van der Schueren E, Van den Bogaert W, Van Wing J. Van Limbergen E, et al. Among authors: van der schueren e, van den bogaert w, van wing j. Eur J Cancer. 1990;26(6):674-9. doi: 10.1016/0277-5379(90)90115-a. Eur J Cancer. 1990. PMID: 2168190
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC, Pierart M, Poortmans PM, Struikmans H, Van der Schueren E, Van Dongen JA, Van Limbergen E, Bartelink H. Vrieling C, et al. Among authors: van der schueren e, van dongen ja, van limbergen e. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):667-76. doi: 10.1016/s0360-3016(99)00215-1. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524421 Clinical Trial.
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Maat B, Van Limbergen E, Bartelink H. Vrieling C, et al. Among authors: van limbergen e. Radiother Oncol. 2000 Jun;55(3):219-32. doi: 10.1016/s0167-8140(00)00210-3. Radiother Oncol. 2000. PMID: 10869738 Clinical Trial.
Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer.
Resch A, Pötter R, Van Limbergen E, Biber E, Klein T, Fellner C, Handl-Zeller L, Langbauer G, Schürer-Waldheim H, Staffen A, Jakesz R, Kubista E, Lehr S, Seitz W. Resch A, et al. Among authors: van limbergen e. Radiother Oncol. 2002 Apr;63(1):47-58. doi: 10.1016/s0167-8140(02)00022-1. Radiother Oncol. 2002. PMID: 12065103
New trends in radiotherapy for breast cancer.
Van Limbergen E, Weltens C. Van Limbergen E, et al. Curr Opin Oncol. 2006 Nov;18(6):555-62. doi: 10.1097/01.cco.0000245327.42281.9f. Curr Opin Oncol. 2006. PMID: 16988575 Review.
213 results